Boston, Massachusetts, USA, November 6, 2026
Servier Pharmaceuticals has announced new clinical and real-world research findings across its growing neuro-oncology portfolio, highlighting advances in the treatment of pediatric and adult gliomas. The company plans to present nine scientific abstracts, including five oral presentations, at the 31st Society for Neuro-Oncology (SNO) Annual Meeting, scheduled for November 12–15, 2026, in Philadelphia, Pennsylvania. The research covers two important targeted cancer therapies: VORANIGO® (vorasidenib) for isocitrate dehydrogenase (IDH)-mutant gliomas and OJEMDA® (tovorafenib) for relapsed or refractory BRAF-altered pediatric low-grade gliomas. The presentations include updated four-year follow-up findings from the Phase 2 FIREFLY-1 study, extended clinical outcomes from the Phase 3 INDIGO trial and real-world evidence evaluating treatment experiences across different glioma populations. These findings aim to improve understanding of treatment durability, disease progression, seizure activity and quality of life among patients with brain tumors. Servier’s expanding research program reflects its commitment to developing targeted therapies for adults and children living with complex neurological cancers, particularly those with significant unmet medical needs.
OJEMDA Shows Long-Term Research Progress in Pediatric Glioma
One of the major highlights of Servier’s SNO 2026 research program is the updated four-year follow-up analysis of the Phase 2 FIREFLY-1 clinical study, evaluating OJEMDA (tovorafenib) in patients with relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG). Pediatric low-grade gliomas are among the most common brain tumors affecting children and are frequently associated with genetic alterations involving the BRAF pathway. Although many children survive these tumors, disease recurrence and repeated treatments can create substantial long-term challenges, including neurological complications and developmental effects. The FIREFLY-1 follow-up will provide additional information about the duration of treatment responses, post-treatment observation and the potential outcomes of retreatment with OJEMDA following disease progression. Tovorafenib is an oral, selective type II RAF kinase inhibitor designed to target abnormal signaling associated with BRAF alterations. The updated research is expected to deepen understanding of its longer-term treatment potential in children whose tumors have returned or failed to respond to previous therapies. The four-year follow-up is particularly important because long-term disease control and treatment durability are major considerations in pediatric brain cancer management.
VORANIGO Advances Clinical Evidence in IDH-Mutant Glioma
Servier will also present important updated findings for VORANIGO (vorasidenib), an oral targeted therapy developed for certain IDH1- and IDH2-mutant gliomas. Two oral presentations will feature extended follow-up analyses from the Phase 3 INDIGO study, which evaluated vorasidenib in patients with Grade 2 IDH-mutant glioma. The extended analysis includes a median overall follow-up duration of 41.6 months and examines treatment outcomes across different histological subgroups and prognostic factors. The reported findings indicate sustained long-term clinical benefits, supporting continued investigation of vorasidenib in this molecularly defined brain cancer population. A separate analysis will examine seizure activity and quality-of-life outcomes, with results suggesting that long-term treatment generally maintained reductions in seizure activity and delayed deterioration in quality of life. These outcomes are important because gliomas can affect neurological function, independence and everyday activities, even when tumor growth is relatively slow. Vorasidenib works by inhibiting mutant IDH1 and IDH2 enzymes, which are involved in the production of the cancer-associated metabolite 2-hydroxyglutarate. By targeting this abnormal metabolic pathway, the treatment aims to address an important molecular driver of IDH-mutant glioma.
Advertisement
Real-World Evidence Expands Understanding of Glioma Treatment
In addition to clinical trial findings, Servier will present two retrospective observational analyses examining the real-world use of VORANIGO in patients with Grade 2 and Grade 3 IDH-mutant gliomas. One analysis evaluated 499 patients with Grade 2 IDH-mutant glioma, focusing on time to next intervention (TTNI), an outcome used to assess the duration before another treatment or intervention becomes necessary. The findings demonstrated short-term real-world effectiveness, with the highest rate observed among patients receiving vorasidenib as their first-line treatment. A second analysis examined a cohort of 80 patients with Grade 3 IDH-mutant glioma, providing emerging evidence about the potential effectiveness of vorasidenib beyond the population studied in the pivotal INDIGO trial. These real-world investigations offer additional insights into treatment patterns and outcomes among patients encountered in routine clinical practice. However, retrospective observational findings should be interpreted carefully because differences in patient characteristics and treatment decisions can influence outcomes. Together, the clinical and real-world research presentations highlight Servier’s growing commitment to precision medicine and targeted neuro-oncology treatments. Further research and longer follow-up will help establish the durability of benefits and identify the patients most likely to benefit from these therapies.
Source: Servier Pharmaceuticals press release
